The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 1×
“9 mo occurred with docetaxel-based chemotherapy compared with mitoxantrone plus prednisone therapy [78].”
BackgroundIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“8 mo [92], and the final results have been reported more recently [93].”
BackgroundAlpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×
“The associated toxicity was mild and, apart from slightly more haematologic toxicity and diarrhoea with Ra 223, did not differ significantly from that in the placebo arm [83].”
Backgroundde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Self-citationEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y.-H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y.-N., Hahn, N., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,896
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Roach, M., Hanks, G., Thames, H., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.029 · Cited by 2,749
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 1,978
Self-citationFizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Saad, F., Gleason, D. M., Murray, R., Tchekmedyian, S., Venner, P., Lacombe, L., Chin, J. L., Vinholes, J. J., Goas, J. A., & Chen, B. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1458 · Cited by 1,656
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Self-citationKantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 982
Smith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., Goldberg, J. M., Khatcheressian, J. L., Leighl, N. B., Perkins, C. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3488 · Cited by 904
Randomized Trial of Short- Versus Long-Course Radiotherapy for Palliation of Painful Bone Metastases
Hartsell, W. F., Scott, C. B., Bruner, D. W., Scarantino, C. W., Ivker, R. A., Roach, M., Suh, J. H., Demas, W. F., Movsas, B., Petersen, I. A., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji139 · Cited by 823
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02163-2 · Cited by 819
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Gravis, G., Fizazi, K., Joly, F., Oudard, S., Priou, F., Esterni, B., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70560-0 · Cited by 744
Trock, B. J. (2008) · JAMA · doi:10.1001/jama.299.23.2760 · Cited by 657
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Hussain, M., Tangen, C. M., Berry, D. L., Higano, C. S., Crawford, E. D., Liu, G., Wilding, G., Prescott, S., Kanaga Sundaram, S., Small, E. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212299 · Cited by 580
Smith, M. R., Kabbinavar, F., Saad, F., Hussain, A., Gittelman, M. C., Bilhartz, D. L., Wynne, C., Murray, R., Zinner, N. R., Schulman, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.529 · Cited by 496
Gravis, G., Boher, J.-M., Joly, F., Soulié, M., Albiges, L., Priou, F., Latorzeff, I., Delva, R., Krakowski, I., Laguerre, B., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.11.005 · Cited by 459
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
AMLING, C. L., BERGSTRALH, E. J., BLUTE, M. L., SLEZAK, J. M., & ZINCKE, H. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)66452-x · Cited by 408
Hoskin, P., Sartor, O., O'Sullivan, J. M., Johannessen, D. C., Helle, S. I., Logue, J., Bottomley, D., Nilsson, S., Vogelzang, N. J., Fang, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70474-7 · Cited by 407
Seidenfeld, J., Samson, D. J., Hasselblad, V., Aronson, N., Albertsen, P. C., Bennett, C. L., & Wilt, T. J. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-7-200004040-00009 · Cited by 398
Carrie, C., Hasbini, A., de Laroche, G., Richaud, P., Guerif, S., Latorzeff, I., Supiot, S., Bosset, M., Lagrange, J.-L., Beckendorf, V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00111-x · Cited by 365
Ost, P., Bossi, A., Decaestecker, K., De Meerleer, G., Giannarini, G., Karnes, R. J., Roach, M., & Briganti, A. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.004 · Cited by 349
Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.01.047 · Cited by 349
AMLING, C. L., BERGSTRALH, E. J., BLUTE, M. L., SLEZAK, J. M., & ZINCKE, H. (2001) · The Journal of Urology · doi:10.1097/00005392-200104000-00020 · Cited by 348
Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv257 · Cited by 322
Self-citationOefelein, M. G., Feng, A., Scolieri, M. J., Ricchiutti, D., & Resnick, M. I. (2000) · Urology · doi:10.1016/s0090-4295(00)00793-7 · Cited by 279
Brockman, J. A., Alanee, S., Vickers, A. J., Scardino, P. T., Wood, D. P., Kibel, A. S., Lin, D. W., Bianco Jr., F. J., Rabah, D. M., Klein, E. A., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.019 · Cited by 245
Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer
Smith, M. R., Boyce, S. P., Moyneur, E., Duh, M. S., Raut, M. K., & Brandman, J. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00033-9 · Cited by 212
Kellokumpu-Lehtinen, P.-L., Harmenberg, U., Joensuu, T., McDermott, R., Hervonen, P., Ginman, C., Luukkaa, M., Nyandoto, P., Hemminki, A., Nilsson, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70537-5 · Cited by 212
Visceral Disease in Castration-resistant Prostate Cancer
Pezaro, C. J., Omlin, A., Lorente, D., Nava Rodrigues, D., Ferraldeschi, R., Bianchini, D., Mukherji, D., Riisnaes, R., Altavilla, A., Crespo, M., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.10.055 · Cited by 207
Armstrong, A. J., Garrett-Mayer, E., de Wit, R., Tannock, I., & Eisenberger, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2514 · Cited by 207
Zumsteg, Z. S., Spratt, D. E., Romesser, P. B., Pei, X., Zhang, Z., Polkinghorn, W., McBride, S., Kollmeier, M., Yamada, Y., & Zelefsky, M. J. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.028 · Cited by 200
Early Salvage Radiotherapy Following Radical Prostatectomy
Pfister, D., Bolla, M., Briganti, A., Carroll, P., Cozzarini, C., Joniau, S., van Poppel, H., Roach, M., Stephenson, A., Wiegel, T., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.08.013 · Cited by 200
Self-citationSmith, M. R., Goode, M., Zietman, A. L., McGovern, F. J., Lee, H., & Finkelstein, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.174 · Cited by 188
Importance of continued testicular suppression in hormone-refractory prostate cancer.
Taylor, C. D., Elson, P., & Trump, D. L. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2167 · Cited by 188
Smith, M. R., Cook, R., Lee, K., & Nelson, J. B. (2011) · Cancer · doi:10.1002/cncr.25762 · Cited by 178
Beresford, M. J., Gillatt, D., Benson, R. J., & Ajithkumar, T. (2010) · Clinical Oncology · doi:10.1016/j.clon.2009.10.015 · Cited by 170
Cost-Effectiveness of Androgen Suppression Therapies in Advanced Prostate Cancer
Bayoumi, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.21.1731 · Cited by 165
Evidence-Based Standards for Cancer Pain Management
Dy, S. M., Asch, S. M., Naeim, A., Sanati, H., Walling, A., & Lorenz, K. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9517 · Cited by 164
Hussain, M., Wolf, M., Marshall, E., Crawford, E. D., & Eisenberger, M. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1868 · Cited by 158
Studer, U. E., Collette, L., Whelan, P., Albrecht, W., Casselman, J., de Reijke, T. M., Knönagel, H., Loidl, W. C., Isorna, S., Sundaram, S. K., et al. (2007) · European Urology · doi:10.1016/j.eururo.2007.12.032 · Cited by 151
Resnick, M. J., Lacchetti, C., Bergman, J., Hauke, R. J., Hoffman, K. E., Kungel, T. M., Morgans, A. K., & Penson, D. F. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2557 · Cited by 144
Early versus deferred androgen suppression in the treatment of advanced prostatic cancer
Wilt, T. J., Nair, B. P., MacDonald, R. H., & Rutks, I. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003506 · Cited by 138
Niraula, S., Le, L. W., & Tannock, I. F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5492 · Cited by 121
Metabolic sequelae associated with androgen deprivation therapy for prostate cancer
Faris, J. E., & Smith, M. R. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283391fd1 · Cited by 105
Maximal androgen blockade for advanced prostate cancer
Schmitt, B. P., Bennett, C. L., Seidenfeld, J., Samson, D. J., & Wilt, T. J. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001526 · Cited by 104
van den Bergh, R. C. N., van Casteren, N. J., den Broeck, T. V., Fordyce, E. R., Gietzmann, W., Stewart, F. J., MacLennan, S., Dabestani, S., Joaquim Bellmunt, B., Bolla, M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.11.023 · Cited by 103
Self-citationChallenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer
Crawford, E. D., Stone, N. N., Yu, E. Y., Koo, P. J., Freedland, S. J., Slovin, S. F., Gomella, L. G., Berger, E. R., Keane, T. E., SIEBER, P. R., et al. (2014) · Urology · doi:10.1016/j.urology.2013.10.026 · Cited by 102
Mitchell, C. R., Lowe, V. J., Rangel, L. J., Hung, J. C., Kwon, E. D., & Karnes, R. J. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.10.069 · Cited by 102
Long-Term Outcomes After High-Dose Postprostatectomy Salvage Radiation Treatment
Goenka, A., Magsanoc, J. M., Pei, X., Schechter, M., Kollmeier, M. A., Cox, B. W., Scardino, P. T., Eastham, J. A., & Zeléfsky, M. J. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.10.077 · Cited by 101
Kunath, F., Grobe, H. R., Rücker, G., Motschall, E., Antes, G., Dahm, P., Wullich, B., & Meerpohl, J. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009266.pub2 · Cited by 85
Horgan, A. M., Šeruga, B., Pond, G. R., Alibhai, S. M. H., Amir, E., de Wit, R., Eisenberger, M. A., & Tannock, I. F. (2014) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2013.12.001 · Cited by 79
Antiandrogen monotherapy: indications and results
Iversen, P. (2002) · Urology · doi:10.1016/s0090-4295(02)01576-5 · Cited by 69
Botrel, T. E. A., Clark, O. A. C., dos Reis, R. B., Pompeo, A. C. L., Ferreira, U., Sadi, M. V., & Bretas, F. F. H. (2014) · BMC Urology · doi:10.1186/1471-2490-14-9 · Cited by 68
Moróte, J., Planas, J., Salvador, C., Raventos, C. X., Catalán, R., & Reventós, J. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2008.08062.x · Cited by 66
Risk factors for male osteoporosis
Conde, F. A., & Aronson, W. J. (2003) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(03)00109-1 · Cited by 52
Soto, D. E., Passarelli, M. N., Daignault, S. D., & Sandler, H. M. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.08.030 · Cited by 46
Collette, L., de Reijke, T. M., & Schröder, F. H. (2003) · European Urology · doi:10.1016/s0302-2838(03)00251-3 · Cited by 39
Cited by
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704174 · Cited by 2,308
Ost, P., Reynders, D., Decaestecker, K., Fonteyne, V., Lumen, N., De Bruycker, A., Lambert, B., Delrue, L., Bultijnck, R., Claeys, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.4853 · Cited by 1,351
Self-citationRebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Self-citationCornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.046 · Cited by 1,079
Self-citationProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Metadata
- Authors
- Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A. M., Joniau, S., Lam, T. B., Mason, M. D., van der Poel, H. G., van der Kwast, T. H., Rouvière, O., Wiegel, T., & Mottet, N.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 71
- Issue
- 4
- Pages
- 630-642
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2511755939
- Cited by
- 1,438
- References
- 71
- FWCI
- 152.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.